Appeal No. 94-1643
Application 07/805,502
1. A method for performing a sterospecific reduction
reaction of an "-ketoamide to an "-hydroxyamide, said method
comprising:
(a) contacting in a reaction mixture the following
species:
(i) said "-ketoamide,
(ii) a reducing agent, and
(iii) monoclonal antibody raised against a hapten
comprising an analog of said "-ketoamide in which the "-
carbonyl group of said "-ketoamide is replaced by a
phosphonate moiety, said monoclonal antibody having been
screened on the basis of its catalytic activity toward
said reduction reaction and
(b) recovering said "-hydroxyamide from said reaction
mixture.
The examiner does not rely on any prior art in rejecting all
the claims under § 112, first paragraph, as being based on a
nonenabling disclosure. Answer, p. 4. In addition, the examiner
urges that the hybridoma cell line used to produce monoclonal
antibody A5 must be deposited in order for the specification to
fully comply with the requirements of the first paragraph of §
112.
Having carefully considered the entire record which includes
the appellants’ main Brief (Paper No. 16) and Reply Brief (Paper
No. 18) and the examiner’s Answer (Paper No. 17), we find
ourselves in full agreement with the appellants’ position.
Accordingly, we reverse the examiner’s rejection.
2
Page: Previous 1 2 3 4 Next
Last modified: November 3, 2007